Key Drivers
- Strong liquidity
- Low leverage
- Weak profitability
AIAI Summary
BLLN has meaningfully shifted from a cash‑burn R&D story to a profitable, high‑gross‑margin diagnostics operator with a strong cash runway—making the next 12 months (hitting the $430–$445M 2026 guide, sustained FCF growth, and broader payer wins) the decisive catalyst for re‑rating while failure to contain SG&A or secure payor coverage would quickly reverse the outlook.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Low leverage
- •Weak profitability
BLLN combines very strong liquidity and low leverage with weak profitability, heavy operating expenses, a large accumulated deficit, and an extremely rich valuation that undermines its investment appeal as of 2025-12-31.
Price Behavior
Key Price Behavior Insights:
- •Short-term bounce
- •Below prior highs
- •Momentum neutral
Price is recovering off the March low and sits just above the last month's 21‑day average (low‑70s) after a bounce, but remains inside a broader downtrend with failure below the March 12 mid‑$60s low risking deeper losses.
Bounce off
Sentiment & News
Key News Insights:
- •Top-line beat
- •Upgraded guidance
- •Elevated investor interest
BillionToOne reported a strong Q4—sales +113% to $96.1M, EPS restored, beat estimates, raised 2026 revenue guidance to $430–$445M and drew heavy trading/analyst buying.
The results and raised guidance should drive positive re-rating risk and near-term upward momentum as prenatal testing growth offsets slower oncology progress
Similar Companies in Healthcare
Other companies in the same sector with AI ratings